Newcastle University

Introduction

My work involves method development and validation of analytical methods (HPLC, LC/MS/MS and AA) for measurement of drug levels in biological matrixes from patients enrolled on clinical trials. Pharmacokinetic analysis, liaising with medical staff and organising shipment of samples.
Also, I am the deputy document controller for the laboratory which involves writing, reviewing and distribution of SOPs and archiving of controlled documents.

• Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EVA, Verrill MW, May FEB, Boddy AV. Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics 2011, 21(12), 808-819.
• Podesta JE, Griffin MJ, Sugar R, Squires MS, Boddy A, Linardopoulos S, Pearson ADJ, Moore AS. Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia. In: Blood: 52nd Annual Meeting of the American Society of Hematology. 2010, Orlando, Florida, USA: American Society of Hematology.
• Cree RTJ, Chishti A, Gascoigne A, Batchelor A, Shaw I, Warnell I, Bullock R, Hayes N, Karat D, Griffin M, Baudouin SV. Changes in interleukin-8 and vascular endothelial growth factor levels in bronchoalveolar lavage samples following oesophagectomy. In: British Journal of Anaesthesia: Meeting of the Intensive Care Society. 2003, London, UK: Oxford University Press.
• Wayman J, Forman D, Griffin M. Monitoring the changing pattern of esophago-gastric cancer: data from a UK regional cancer registry. Cancer Causes & Control 2001, 12(10), 943-949.